American Century Companies Inc. raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 128.5% during the second quarter, HoldingsChannel.com reports. The fund owned 416,000 shares of the biopharmaceutical company’s stock after acquiring an additional 233,928 shares during the quarter. American Century Companies Inc.’s holdings in Celldex Therapeutics were worth $15,396,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of CLDX. Victory Capital Management Inc. acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at $288,000. Charles Schwab Investment Management Inc. lifted its holdings in Celldex Therapeutics by 13.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock valued at $16,236,000 after purchasing an additional 47,844 shares during the last quarter. UBS Group AG boosted its position in Celldex Therapeutics by 645.9% in the fourth quarter. UBS Group AG now owns 158,092 shares of the biopharmaceutical company’s stock valued at $6,270,000 after buying an additional 136,897 shares in the last quarter. Trexquant Investment LP bought a new stake in Celldex Therapeutics during the fourth quarter worth about $1,246,000. Finally, Aigen Investment Management LP bought a new stake in Celldex Therapeutics during the fourth quarter worth about $251,000.
Celldex Therapeutics Stock Up 0.2 %
Shares of CLDX stock opened at $41.24 on Friday. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -14.47 and a beta of 1.56. Celldex Therapeutics, Inc. has a 12 month low of $22.11 and a 12 month high of $53.18. The stock has a 50-day moving average price of $38.54 and a 200 day moving average price of $38.74.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on CLDX shares. Wolfe Research assumed coverage on Celldex Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 target price on the stock. Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price for the company. Wells Fargo & Company increased their price objective on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Monday, August 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $63.83.
Read Our Latest Research Report on Celldex Therapeutics
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Further Reading
- Five stocks we like better than Celldex Therapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- How to Plot Fibonacci Price Inflection Levels
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report).
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.